Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2):167-80

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  PET-CT FOR TAILORING THERAPY OF SOLID TUMORSFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2):167-80

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

[18F]FDG-PET-CT for early monitoring of tumor response: when and why

Storto G. 1, Nicolai E. 2, Salvatore M. 3

1 IRCCS, CROB, Rionero in Vulture, Potenza, Italy 2 SDN Foundation, Institute of Diagnostic and Nuclear Development Naples, Italy 3 Department of Biomorphological and Functional Sciences, University “Federico II”, Naples, Italy


FULL TEXT  


18F-fluorodeoxyglucose positron emission tomography ([18F]FDG PET) has been recognized as a suitable tool in tumor response assessment of patients complaining with solid tumors who have undergone chemo- and radiotherapy. It offers the advantage of functional tissue characterization, which is independent from morphologic criteria allowing to differentiate disease relapse from therapy-induced fibrosis. At present, there is a growing body of evidence that PET semi-quantitative assessment of treatment-induced changes in tumor [18F]FDG avidity may predict early tumor response and patient outcome. Patient management might be changed. For instance, in non responder patients this novel diagnostic approach would hamper useless “wait and watch” attitude in implementing further options or identifying those needing additional therapeutic strategies. On the other hand, for those patients revealing promptly a favourable metabolic response a cost-sparing approach could be implemented avoiding expensive diagnostic procedures during the follow-up as well as the risk of over-treating. In any case, since even a partial metabolic response may be an indication for continuing therapy, the advantage of metabolic assessment over conventional procedures may be clinically relevant. Although a morphological assessment has been considered for long time the standard for detecting therapy response, limitations of conventional computed tomography-based evaluation in solid tumors are well-known. PET provides an independent means of assessing malignancy. However, no consensus has been achieved until now regarding the optimal timing in performing PET during or at completion of treatment.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail